Five-year follow-up of patients with chronic c hepatitis and sustained virological response

Revista Espanola de Enfermedades Digestivas

Volumn 103, Issue 2, 2011, Pages 56-61

  Puig del Castillo, I ^a   Miquel Planas, M ^a,b   Vergara Gomez M ^a,b   Cebollero Agusti A ^c   Gallach Montero, M ^a   Dalmau Obrador, B ^a,b   Gil Prades, M ^a,b   Casas Rodrigo, M ^a   Sanchez Delgado J ^a,b   Tomas Tutusaus R ^c   Gavarro Puig A ^c  

^a PARC TAULÍ HOSPITAL UNIVERSITARI   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c Servicio de Oncología Médica   (Spain)

Author keywords

Chronic C hepatitis; Pegylated interferon alfa 2a; Pegylated interferon alfa 2b; Ribavirin

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ARTICLE; DESCRIPTIVE RESEARCH; FOLLOW UP; GENOTYPE; HEPATITIS C; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; RECURRENT INFECTION; TREND STUDY;

EID: 80051538971     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: 10.4321/S1130-01082011000200002     Document Type: Article

References (41)

1. Bruguera M, Forns X. Hepatitis en España. Med.Clin.(Barc.) 2006;127: 113-7.
2. Dienstag JL, McHutchison JG. American Gastroenterological Associationtechnical review on the management of hepatitis C. Gastroenterology 2006;130: 231-64.
3. Dominguez M, Colmenero J, Bataller R. Tratamiento de la fibrosishepática. Gastroenterol. Hepatol. 2009; 32: 627-32.
4. Camma C, Giunta M, Pinzello G, Morabito A, Verderio P, Pagliaro L. Chronic hepatitis C and interferon alpha: conventional and cumulativemeta-analyses of randomized controlled trials. Am. J. Gastroenterol.1999; 94: 581-95.
5. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management,and treatment of hepatitis C: an update. Hepatology 2009; 49:1335-74.
6. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, GoodmanZ, et al. Impact of pegylated interferon alfa-2b and ribavirin onliver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303-13.
7. Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnu L, Mazzella G, et al. Sustained virological response to interferon-alpha is associatedwith improved outcome in HCV-related cirrhosis: a retrospectivestudy. Hepatology 2007; 45: 579-87.
8. Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, et al. Long-term histologic improvement and loss of detectable intrahepaticHCV RNA in patients with chronic hepatitis C and sustainedresponse to interferon-alpha therapy. Ann. Intern. Med. 1997;127: 875-81.
9. Maylin S, Martinot-Peignoux M, Moucari R, Boyer N, Ripault MP, Cazals-Hatem D, et al. Eradication of hepatitis C virus in patients successfullytreated for chronic hepatitis C. Gastroenterology 2008; 135: 821-9.
10. George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, Hoffmann J, Di Bisceglie AM. Clinical, virologic, histologic, and biochemicaloutcomes after successful HCV therapy: a 5-year follow-up of 150patients. Hepatology 2009; 49: 729-38.
11. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin comparedwith interferon alfa-2b plus ribavirin for initial treatment of chronichepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
12. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitisC virus infection. N. Engl. J. Med. 2002; 347: 975-82.
13. Hadziyannis SJ, Sette H, Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapyin chronic hepatitis C: a randomized study of treatment duration andribavirin dose. Ann. Intern. Med. 2004;140:346-55.
14. Vergara M, Gallach M, Dalmau B, Gil M, Miquel M, Rudi N, et al. [Results of pegylated interferon and ribavirin for the treatment of chronichepatitis C in clinical practice: a 5-year experience]. Gastroenterol.Hepatol. 2008; 31: 274-9.
15. Veldt BJ, Saracco G, Boyer N, Camma C, Bellobuono A, Hopf U, et al. Long term clinical outcome of chronic hepatitis C patients with sustainedvirological response to interferon monotherapy. Gut 2004; 53:1504-8.
16. Kelly D, Haber B, Gonzalez-Peralta RP, Murray KF, Jonas MM, Molleston JP, et al. Sustained virological response to interferon alfa-2bplus ribavirin predicts long-term clearance of HCV in pediatric patientsat 5 year follow-up. J Hepatology 2008;48:298-9.
17. Giannini EG, Basso M, Savarino V, Picciotto A. Sustained virologicalresponse to pegylated interferon and ribavirin is maintained duringlong-term follow-up of chronic hepatitis C patients*. Aliment.Pharmacol.Ther. 2010;31:502-8.
18. Swain M, Lai MY, Shiffmann ML al. Treatment of patients with chronichepatitis C (CHC) with peginterferon alfa-2a (40 KD) (Pegasys)alone or in combination with ribavirin (copegus) results inlong-lasting sustained virological response. J Hepatol 2003;38 (suppl2):175.
19. Maylin S, Martinot-Peignoux M, Ripault MP, Moucari R, Cardoso AC, Boyer N, et al. Sustained virological response is associated withclearance of hepatitis C virus RNA and a decrease in hepatitis C virusantibody. Liver Int. 2009; 29: 511-7.
20. Ciancio A, Smedile A, Giordanino C, Colletta C, Croce G, Pozzi M, et al. Long-term follow-up of previous hepatitis C virus positive nonrespondersto interferon monotherapy successfully retreated withcombination therapy: are they really cured? Am.J Gastroenterol.2006;101:1811-6.
21. Castillo I, Bartolome J, Quiroga JA, Barril G, Carreno V. Presence of HCV-RNA after ultracentrifugation of serum samples during the follow-up of chronic hepatitis C patients with a sustained virologicalresponse may predict reactivation of hepatitis C virus infection. Aliment.Pharmacol. Ther. 2009; 30: 477-86.
22. Sánchez Tapias J. Sustained virological response and clinical outcomesin chronic hepatitis C. In: Arroyo V, Abraldes JG, Sánchez TapiasJM, Forns X, Bataller R, Rodés J, eds. Treatment of liver disease.2009:67-72.
23. [Consensus document of the Spanish Association for the Study of theLiver on the treatment of hepatitis B and C virus infections.]. Gastroenterol.Hepatol. 2006;29 Suppl 2:216-30.
24. Bejarano G, Vergara M, Dalmau B, Puig J, Bella MR, Suarez D, et al. Prospective evaluation of liver fibrosis in chronic viral hepatitis Cinfection using the Sabadell NIHCED (Non-Invasive Hepatitis-CRelatedCirrhosis Early Detection) index. Rev. Esp. Enferm. Dig.2009;101: 325-35.
25. Obrador BD, Prades MG, Gomez MV, Domingo JP, Cueto RB, Rue M, et al. A predictive index for the diagnosis of cirrhosis in hepatitisC based on clinical, laboratory, and ultrasound findings. Eur. J Gastroenterol.Hepatol 2006; 18: 57-62.
26. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system forassessing histological activity in asymptomatic chronic active hepatitis.Hepatology 1981; 1: 431-5.
27. Cuadrado A, Crespo J. Hypertransaminasemia in patients with negativeviral markers. Rev. Esp. Enferm. Dig. 2004; 96: 484-500.
28. Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, et al. Histologic improvement of fibrosis in patients with hepatitisC who have sustained response to interferon therapy. Ann.Intern.Med. 2000; 132: 517-24.
29. Gerotto M, Dal PF, Bortoletto G, Ferrari A, Pistis R, Sebastiani G, et al. Hepatitis C minimal residual viremia (MRV) detected by TMA atthe end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse.J Hepatol 2006; 44: 83-7.
30. Radkowski M, Gallegos-Orozco JF, Jablonska J, Colby TV, Walewska-Zielecka B, et al. Persistence of hepatitis C virus in patients successfullytreated for chronic hepatitis C. Hepatology 2005; 41: 106-14.
31. Castillo I, Rodriguez-Inigo E, Lopez-Alcorocho JM, Pardo M, Bartolome J, Carreno V. Hepatitis C virus replicates in the liver of patientswho have a sustained response to antiviral treatment. Clin. Infect.Dis. 2006; 43: 1277-83.
32. Gallegos-Orozco JF, Rakela J, Rosati MJ, Vargas HE, Balan V. Persistenceof hepatitis C virus in peripheral blood mononuclear cells ofsustained viral responders to pegylated interferon and ribavirin therapy.Dig. Dis. Sci. 2008; 53: 2564-8.
33. Desmond CP, Roberts SK, Dudley F, Mitchell J, Day C, Nguyen S, et al. Sustained virological response rates and durability of the responseto interferon-based therapies in hepatitis C patients treated inthe clinical setting. J Viral Hepat. 2006; 13: 311-5.
34. Formann E, Steindl-Munda P, Hofer H, Jessner W, Bergholz U, Gurguta C, et al. Long-term follow-up of chronic hepatitis C patientswith sustained virological response to various forms of interferon-basedanti-viral therapy. Aliment. Pharmacol. Ther. 2006; 23: 507-11.
35. Fontaine H, Nalpas B, Lagneau JL, Zylberberg H, Bréchot C, Pol S. Histological and virological evolution of long term response after ribavirinand interferon-á combination. J Hepatology 2000;32 [Supplement2]:103.
36. Khokhar N. Late relapse in chronic hepatitis C after sustained viralresponse to interferon and ribavirin. J Gastroenterol.Hepatol 2004;19: 471-2.
37. Manns M, Lindsay KL, Gordon SC, Pockros PJ, Haussinger D, Hadziyannis SJ, et al. Sustained virological response after peginterferonalfa-2b and ribavirn treatment predicts long-term clearance of HCVat 5-year follow-up. J Hepatology 2008;48 (Suppl2): S300.
38. McHutchison JG, Shiffman ML, Gordon SC, Lindsay KL, Morgan TR, Norkrans G, et al. Sustained virologic response (SVR) to interferon-alpha-2b +/- ribavirin therapy at 6 months reliably predicts longtermclearance of HCV at 5-year follow-up. J Hepatol 2006;44[Suppl2]: 275.
39. Moreno M, Perez-Alvarez R, Rodrigo L, Perez-Lopez R, Suarez-Leiva P. Long-term evolution of serum and liver viral markers in patientstreated for chronic hepatitis C and sustained response. J ViralHepat. 2006; 13: 28-33.
40. Ponsoda P, Blanc P, Philippe G, Ramos J, Ducos J, Larrey D. Absenceof long term relapse in patients with a good virological response at6 months after treatment for chronic hepatitis C. J Hepatology 2002;36[Supplement 1]:125.
41. Soriano V, Maida I, Nunez M, Garcia-Samaniego J, Barreiro P, Martin-Carbonero L, et al. Long-term follow-up of HIV-infected patientswith chronic hepatitis C virus infection treated with interferon-basedtherapies. Antivir. Ther. 2004; 9: 987-92.